

# Inhibition of the renin-angiotensin-aldosterone system in diabetic nephropathy: focusing on renal fibrosis

Sandor Koszegi<sup>1,4</sup>, Judit Hodrea<sup>1,4</sup>, Lilla Lenart<sup>1,4</sup>, Adam Hosszu<sup>1,4</sup>, Edgar Szkibinskij<sup>1</sup>, Laszlo Wagner<sup>3</sup>, Adam Vannay<sup>2,4</sup>, Tivadar Tulassay<sup>2,4</sup>, Attila J Szabo<sup>2,4</sup>, Andrea Fekete<sup>1,4</sup>


<sup>1</sup>MTA-SE „Lendület” Diabetes Research Group; <sup>2</sup>MTA-SE Pediatrics and Nephrology Research Group, <sup>3</sup>Department of Transplantation and Surgery; <sup>4</sup>1st Department of Pediatrics; Semmelweis University, Budapest

## Introduction

- Nowadays 366 million people suffer from diabetes worldwide and this number will exceed 552 million by 2030. <sup>1</sup>
- In diabetes the **renin-angiotensin-aldosterone system (RAAS)** is highly activated. <sup>2</sup>
- The elevated renal **angiotensin (ANG) II** induces renal fibrosis via different growth factors. <sup>3</sup>
- One of the most characteristic markers of renal fibrosis is the **increased level of  $\alpha$ -smooth muscle actin ( $\alpha$ SMA)**. <sup>4</sup>
- **Platelet-derived growth factor (PDGF)** plays a key role in fibrosis. <sup>5</sup>
- During fibrosis, isoforms of PDGF B and D, and receptor PDGF  $\beta$  are involved in the activation of fibroblasts. <sup>6</sup>

## Aims

Our aim was to investigate the effect of various RAAS inhibitors on diabetes induced renal fibrosis.



## Methods

- After 5 weeks of streptozotocin (65 mg / bwkg ip.) induced diabetes male Wistar rats were treated for 2 weeks with ACE inhibitor **enalapril** (40 mg x bwkg / day) or **ramipril** (10  $\mu$ g / bwkg / day), ARB **losartan** (20 mg / bwkg / day) or aldosterone antagonists **spironolactone** or **eplerenone** (50-50 mg / bwkg / day). Untreated diabetic (D) and healthy animals (C) served as controls (n=6/group).
- Human kidney 2 (HK-2) proximal tubular cells were cultured in *normal* (5,5 mM) or *high glucose* solution (35 mM) or in *mannitol* (35 mM) as osmotic control.
- Normal rat kidney (NRK-49F) fibroblasts were treated with PDGF (10 ng/mL) and  $\alpha$ SMA protein level was detected.
- Mesangial matrix expansion and tubulo-interstitial fibrosis were analyzed on PAS or Masson's trichrome stained kidney sections.
- Protein levels of  $\alpha$ SMA in HK-2, NRK-49F and kidney tissue were measured by Western blot and the localization of PDGFR $\beta$  and  $\alpha$ SMA was detected by immunofluorescent staining

## SUMMARY - CONCLUSIONS

- High glucose increases the PDGF production of proximal tubular cells, that in turn induces the  $\alpha$ SMA production in renal fibroblast.
- This changes in the proximal cells are likely to be due to the presence of hyperglycemia than to glucose induced hyperosmolality.
- This mechanism also contributes to the development of renal fibrosis seen in DNP.
- RAAS blockers ameliorate this process by directly acting on renal fibroblasts which could serve as a new therapeutic potential in the treatment of renal fibrosis.

## Results

### 1. RAAS inhibitors ameliorated diabetes induced renal damage




Figure 1. Representative PAS (a) and Masson's trichrome (b) stained renal sections of each group. Diabetes induced mesangial matrix expansion and tubulo-interstitial fibrosis were ameliorated by each RAAS blocker. (a: 400x magnification, scale bar 50  $\mu$ m,  $\rightarrow$ : arteriola,  $\rightarrow$ : mesangial matrix; b: 200x magnification, scalebar 100  $\mu$ m,  $\Rightarrow$  interstitial fibrosis). (\* $p$ <0.05 vs. Control;  $\S$  $p$ <0.05 vs. Diabetes (n=6/group)).

### 2. Glucose, but not mannitol increased $\alpha$ SMA level in HK-2 cells




Figure 2.

High glucose induced elevation of  $\alpha$ SMA and PDGF B protein levels; while no change was observed in the case of osmotic control mannitol. (\* $p$ <0.05 vs. Control;  $\S$  $p$ <0.05 vs. Glucose (n=6/group))

### 3. RAAS inhibitors decreased protein level of $\alpha$ SMA in vivo and in vitro




Figure 3.

Diabetes induced elevation of  $\alpha$ SMA protein level in the kidney (a) was diminished by various RAAS inhibitors (\*\* $p$ <0.001 vs. Control;  $\S\S\S$  $p$ <0.001 vs. Diabetes (n=6/group)). 24h (b) and 48h (c) PDGF- treated normal rat kidney fibroblasts (NRK-49F) produced more  $\alpha$ SMA protein which decreased by RAAS blockers. (\* $p$ <0.05 vs. Control;  $\S$  $p$ <0.05 vs. PDGF (n=6/group)).

### 4. Localisation of $\alpha$ SMA and PDGFR $\beta$ in diabetic kidney




Figure 4.

Glomeruli showed no  $\alpha$ SMA staining in controls, while slight increase was observed in diabetic rats. Each RAAS blocker treatment decreased  $\alpha$ SMA within glomeruli. The staining of PDGF receptor was more intensive in tubuli. Tubular cells showed no  $\alpha$ SMA staining in controls, while a definitive intracellular staining was visible in diabetic kidneys. Aldosterone antagonists decreased  $\alpha$ SMA within tubuli and translocated the protein from the cytoplasm towards the basolateral membrane. The staining of the tubulo-interstitially localized PDGF receptor was more intensive in diabetic rats than in controls. (630x magnification, scale bar 20  $\mu$ m, green -  $\alpha$ SMA, red - PDGFR $\beta$ , blue - nuclei, Hoechst)

#### Acknowledgment:

This work was supported by Lendület Research Grant (LP008/2014) and grants of OTKA NK84087/2010, -K108688, KMR12-1-2012-0074.

#### References:

1. International Diabetes Federation - <http://www.idf.org>.
2. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. *J Am Soc Nephrol*. 2006; 17: 2985-2991.
3. Rodriguez-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, Rodriguez-Diez R, Selgas R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. *Pharm Res*. 2008; 25: 2447-2461.
4. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M. Transdifferentiation of cultured tubular cells induced by hypoxia. *Kidney Int*. 2004; 65: 871-878.
5. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. *J Am Soc Nephrol*. 2008 Jan;19(1):12-23.
6. Ostendorf T, Eitner F, Floege J. The PDGF family in renal fibrosis. *Pediatr Nephrol*. 2012 Jul;27(7):1041-50.